Abiopharma

🔍 Prior Stephen David (Executive)

Company: AN2 Therapeutics, Inc. (ANTX)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 3,604 shares of Common Stock at $1.003 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 61,944.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,858 shares of Common Stock at $1.012 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 59,086.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
• F2: Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.